Y Deugnier

Summary

Country: France

Publications

  1. ncbi Iron and hepatocellular carcinoma
    Y Deugnier
    Clinique des Maladies du Foie, INSERM U522, Hopital Pontchaillou, Rennes, France
    J Gastroenterol Hepatol 16:491-4. 2001
  2. ncbi Modifying factors of the HFE hemochromatosis phenotype
    Yves Deugnier
    Service des Maladies du Foie, INSERM CIC 0203, Université de Rennes 1 and IFR 140, CHU Pontchaillou, 35033 Rennes, France
    Expert Rev Gastroenterol Hepatol 2:531-40. 2008
  3. ncbi Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people
    Yves Deugnier
    Service des Maladies du Foie and INSERM U522, Rennes, France
    Br J Haematol 118:1170-8. 2002
  4. ncbi Iron and the liver: update 2008
    Yves Deugnier
    Service des Maladies du Foie, INSERM CIC 0203, Université de Rennes 1 and IFR 140, CHU Pontchaillou, 35033 Rennes, France
    J Hepatol 48:S113-23. 2008
  5. ncbi Pathology of hepatic iron overload
    Yves Deugnier
    Liver Unit and CIC INSERM 0203, Pontchaillou University Hospital, Rennes 35033, France
    World J Gastroenterol 13:4755-60. 2007
  6. ncbi [Steatohepatitis and metabolic and nutritional abnormalities]
    Yves Deugnier
    Maladies du Foie et Centre d'Investigation Clinique, CHU Pontchaillou, 35033 Rennes
    Gastroenterol Clin Biol 27:B9-12. 2003
  7. ncbi Iron and liver cancer
    Yves Deugnier
    Clinique des Maladies du Foie and Centre d Investigation Clinique, CHU Pontchaillou, 35033 Rennes, France
    Alcohol 30:145-50. 2003
  8. ncbi [Screening for hereditary HFE hemochromatosis]
    Yves Deugnier
    Service des Maladies du Foie, Centre de dépistage familial de l hémochromatose, CHU Pontchaillou, Rennes
    Presse Med 36:1292-4. 2007
  9. ncbi Pathology of hepatic iron overload
    Yves Deugnier
    CHU Rennes, Liver Unit, Rennes, France
    Semin Liver Dis 31:260-71. 2011
  10. ncbi [Hemochromatosis]
    Yves Deugnier
    , CHU Pontchaillou, 35033 Rennes
    Rev Prat 54:669-73. 2004

Collaborators

Detail Information

Publications58

  1. ncbi Iron and hepatocellular carcinoma
    Y Deugnier
    Clinique des Maladies du Foie, INSERM U522, Hopital Pontchaillou, Rennes, France
    J Gastroenterol Hepatol 16:491-4. 2001
    ....
  2. ncbi Modifying factors of the HFE hemochromatosis phenotype
    Yves Deugnier
    Service des Maladies du Foie, INSERM CIC 0203, Université de Rennes 1 and IFR 140, CHU Pontchaillou, 35033 Rennes, France
    Expert Rev Gastroenterol Hepatol 2:531-40. 2008
    ..Better identification of acquired and genetic modifiers of iron burden and iron-related organ damage is needed to improve the preventive, diagnostic and therapeutic management of HFE hemochromatosis...
  3. ncbi Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people
    Yves Deugnier
    Service des Maladies du Foie and INSERM U522, Rennes, France
    Br J Haematol 118:1170-8. 2002
    ..However, in premenopausal women, large-scale screening remains to be justified with respect to the natural history of haemochromatosis and should be directly genotypic...
  4. ncbi Iron and the liver: update 2008
    Yves Deugnier
    Service des Maladies du Foie, INSERM CIC 0203, Université de Rennes 1 and IFR 140, CHU Pontchaillou, 35033 Rennes, France
    J Hepatol 48:S113-23. 2008
    ....
  5. ncbi Pathology of hepatic iron overload
    Yves Deugnier
    Liver Unit and CIC INSERM 0203, Pontchaillou University Hospital, Rennes 35033, France
    World J Gastroenterol 13:4755-60. 2007
    ....
  6. ncbi [Steatohepatitis and metabolic and nutritional abnormalities]
    Yves Deugnier
    Maladies du Foie et Centre d'Investigation Clinique, CHU Pontchaillou, 35033 Rennes
    Gastroenterol Clin Biol 27:B9-12. 2003
  7. ncbi Iron and liver cancer
    Yves Deugnier
    Clinique des Maladies du Foie and Centre d Investigation Clinique, CHU Pontchaillou, 35033 Rennes, France
    Alcohol 30:145-50. 2003
    ..Findings obtained from experimental work are not conclusive with respect to a direct carcinogenic role of iron, but they support a carcinogenic or co-carcinogenic role of iron in chemically induced carcinogenesis...
  8. ncbi [Screening for hereditary HFE hemochromatosis]
    Yves Deugnier
    Service des Maladies du Foie, Centre de dépistage familial de l hémochromatose, CHU Pontchaillou, Rennes
    Presse Med 36:1292-4. 2007
    ..This type of screening is cost-effective. One obstacle today is that the national health insurance fund does not reimburse the HFE test...
  9. ncbi Pathology of hepatic iron overload
    Yves Deugnier
    CHU Rennes, Liver Unit, Rennes, France
    Semin Liver Dis 31:260-71. 2011
    ..The identification of iron overload, the description of its cellular and lobular distribution, semiquantitative assessment of its amount, and inventory of associated lesions, especially fibrosis, are the pathologist's main objectives...
  10. ncbi [Hemochromatosis]
    Yves Deugnier
    , CHU Pontchaillou, 35033 Rennes
    Rev Prat 54:669-73. 2004
  11. ncbi [Should we support large-scale screening for genetic haemochromatosis in France?]
    Yves Deugnier
    Service des Maladies du Foie Centre de Dépistage Familial de l Hémochromatose, INSERM 0203, CHU Pontchaillou 35033 Rennes
    Bull Acad Natl Med 188:265-72; discussion 272-3. 2004
    ....
  12. ncbi [Diagnosis of iron overload]
    Yves Deugnier
    Service des Maladies du Foie, hôpital CHU Pontchaillou, 35033 Rennes Cedex 9
    Rev Prat 56:2118-22. 2006
    ....
  13. ncbi [Iron overload. Diagnosing and treating prior to complications]
    Yves Deugnier
    Service des maladies du foie et Centre d'lnvestigation Clinique CIC 0203, , 35033 Rennes Cedex 9
    Rev Prat 56:2109-10. 2006
  14. ncbi [Acquired and genetic factors influencing the penetrance of HFE haemochromatosis]
    Yves Deugnier
    CIC Inserm 0203, IFR 140, CHU Pontchaillou, 35033 Rennes
    Bull Acad Natl Med 192:873-81; discussion 881. 2008
    ..Further studies of these modifiers are needed to improve the management of C282Y homozygotes, at both the individual and the population levels...
  15. ncbi [Human hepatic iron overload syndromes]
    Yves Deugnier
    Service des maladies du foie et CIC Inserm 0203, CHU Pontchaillou, Rennes
    Bull Acad Natl Med 189:1665-76; discussion 1676-7. 2005
    ..Acquired iron overload syndromes can be related to metabolic syndrome (insulin resistance syndrome), end-stage cirrhosis, or hematological disorders such as thalassemia and refractory anaemia...
  16. ncbi Increased body iron stores in elite road cyclists
    Yves Deugnier
    Service des Maladies du Foie and INSERM U522, Laboratoire de Physiologie, Laboratoire d anatomie pathologique B, Departement de Radiologie, Rennes, France
    Med Sci Sports Exerc 34:876-80. 2002
    ..One third of French elite road cyclists were found to have hyperferritinemia on antidoping control tests performed during the Tour de France in 1998...
  17. ncbi Improvement in liver pathology of patients with ?-thalassemia treated with deferasirox for at least 3 years
    Yves Deugnier
    Liver Disease Unit and Inserm U 991, Department of Pathology, University Hospital Pontchaillou, Rennes, France
    Gastroenterology 141:1202-11, 1211.e1-3. 2011
    ..We studied the effects of the oral iron chelator deferasirox on liver fibrosis and necroinflammation in a large population of patients with iron overload ?-thalassemia...
  18. ncbi The iron driven pathway of hepcidin synthesis
    Y Deugnier
    INSERM U 991, CIC 0203, CHU, Universite de Rennes 1, Rennes, France
    Gastroenterol Clin Biol 34:351-4. 2010
    ..Mutations in these genes lead to a phenotype of hemochromatosis. Recently, the bone morphogenetic protein 6 was shown to be the key endogenous ligand involved in the cascade regulating hepcidin synthesis...
  19. ncbi A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria
    P Brissot
    Clinique des Maladies du Foie, Pontchaillou University Hospital, Rennes, France
    J Hepatol 30:588-93. 1999
    ....
  20. ncbi Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients
    B Turlin
    Laboratory of Pathology B, University Hospital Pontchaillou, Rennes, France
    Am J Clin Pathol 116:263-70. 2001
    ..Iron overload in IR-HIO was histologically different from that in genetic hemochromatosis...
  21. ncbi Venesection therapy of insulin resistance-associated hepatic iron overload
    M H Mendler
    Clinique des Maladies du Foie, CHU Pontchaillou, Rennes, France
    J Hepatol 35:344-9. 2001
    ..Based on these data and on studies indicating that iron excess is associated with increased risk for hepatic fibrosis, cancer and cardiovascular disorders, venesection therapy can be recommended in IR-HIO patients...
  22. ncbi Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis
    D Guyader
    Clinique des Maladies du Foie and INSERM Unité 49, Rennes, France
    Gastroenterology 115:929-36. 1998
    ..The aim of this study was to define noninvasive factors predictive of severe fibrosis (bridging fibrosis or cirrhosis) to avoid unnecessary liver biopsies in such patients...
  23. ncbi Bone mineral density in men with genetic hemochromatosis and HFE gene mutation
    P Guggenbuhl
    Rheumatology Department, University Hospital, Rennes, France
    Osteoporos Int 16:1809-14. 2005
    ..399). We conclude that there is significant bone loss in HFE-related hemochromatosis that cannot solely be explained by hypogonadism or cirrhosis. Further investigations are needed to determine the role of iron overload itself...
  24. ncbi Circadian variations of transferrin saturation levels in iron-overloaded patients: implications for the screening of C282Y-linked haemochromatosis
    Anne Guillygomarc'h
    Service des Maladies du Foie, CHU Pontchaillou, Rennes, France
    Br J Haematol 120:359-63. 2003
    ..00 hours and 36% at 00.00 hours. In conclusion, for screening studies of C282Y homozygosity, determination of transferrin saturation may be performed at any time during the day...
  25. ncbi Effects of phlebotomy therapy on cytochrome P450 2e1 activity and oxidative stress markers in dysmetabolic iron overload syndrome: a randomized trial
    F Laine
    Centre d Investigation Clinique INSERM 0203, CHU Pontchaillou, 35033 Rennes, France
    Aliment Pharmacol Ther 24:1207-13. 2006
    ..To assess the effects of iron removal on cytochrome P450 2E1 activity and oxidative stress in dysmetabolic iron overload syndrome...
  26. ncbi Phenotypic expression in detected C282Y homozygous women depends on body mass index
    Fabrice Lainé
    Centre d Investigation Clinique INSERM 0203, CHU Pontchaillou, 35033 Rennes, France
    J Hepatol 43:1055-9. 2005
    ..The aim of this study was to identify the clinical and biochemical factors associated with non-expression of the disease as defined as transferrin saturation <45%...
  27. ncbi Redox active plasma iron in C282Y/C282Y hemochromatosis
    Caroline Le Lan
    Service des Maladies du Foie, , University Hospital Pontchaillou, Rennes 35033, France
    Blood 105:4527-31. 2005
    ..LPI is present in C282Y/C282Y hemochromatosis and may be a marker of toxicity due to its potential for catalyzing the generation of reactive oxygen radicals in vivo...
  28. ncbi A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis
    Marie Laure Island
    INSERM U522, University of Rennes 1, Hopital Pontchaillou, Rennes Cedex, France
    Haematologica 94:720-4. 2009
    ..In conclusion, our results suggest that a mutation in the BMP-RE of hepcidin promoter may impact on human iron metabolism...
  29. ncbi Low penetrant hemochromatosis phenotype in eight families: no evidence of modifiers in the MHC region
    S Sachot
    , Rennes, France
    Blood Cells Mol Dis 27:518-29. 2001
    ..The haplotypes presented no significant difference between the probands and their unaffected relatives. These studies suggest that neither HFE polymorphism nor genes surrounding HFE are able to modulate HFE expression...
  30. ncbi Non-invasive assessment of hepatic iron stores by MRI
    Y Gandon
    Fédération d Imagerie Médicale, CHU Pontchaillou, Rennes, France
    Lancet 363:357-62. 2004
    ..We aimed to assess the accuracy of a simple, rapid, and easy to implement MRI procedure to detect and quantify hepatic iron stores...
  31. ncbi Increase in glycosylated and nonglycosylated serum ferritin in chronic alcoholism and their evolution during alcohol withdrawal
    R Moirand
    INSERM U 49, , Rennes, France
    Alcohol Clin Exp Res 15:963-9. 1991
    ....
  32. ncbi In patients with cirrhosis, serum albumin determination should be carried out by immunonephelometry rather than by protein electrophoresis
    M H Mendler
    Clinique des Maladies du Foie and INSERM U 522, Rennes, France
    Eur J Gastroenterol Hepatol 11:1405-11. 1999
    ..Serum albumin is a key parameter for prognosis in cirrhosis. We compared levels of serum albumin determined by both protein electrophoresis and immunonephelometry, with special reference to the Child-Pugh classification...
  33. ncbi [Iron overload and public health]
    Y Deugnier
    Clinique des Maladies du Foie, Hopital Pontchaillou, Rennes
    Bull Acad Natl Med 184:365-73; discussion 374-6. 2000
    ..This might extend markedly the impact of iron overload in public health and lead to broaden screening and prevention to all iron overload conditions...
  34. ncbi Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients
    E Boucher
    Clinique des Maladies du Foie et INSERM U49, Hopital Pontchaillou Rennes, France
    Dig Liver Dis 32:29-33. 2000
    ....
  35. ncbi Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C
    Dominique Guyader
    Liver unit and INSERM U522, University of Rennes, France
    J Hepatol 46:587-95. 2007
    ..However, the real impact of iron is still controversial. The study was undertaken to determine the effect of confounding variables. All factors known to influence both iron overload and fibrosis were taken into account...
  36. ncbi Current approach to hemochromatosis
    Pierre Brissot
    Liver Disease Unit, Liver Research Unit Inserm U 522, IFR 140, University of Rennes1, Hemochromatosis Reference Center, Laboratory of Molecular Genetics, University Hospital Pontchaillou, Rennes, France
    Blood Rev 22:195-210. 2008
    ..Phlebotomies remain an essential therapeutic tool but the improved understanding of the intimate mechanisms underlying these diseases paves the road for innovative therapeutic approaches...
  37. ncbi HFE based re-evaluation of heterozygous hemochromatosis
    Romain Moirand
    Clinique des Maladies du Foie, Rennes, France
    Am J Med Genet 111:356-61. 2002
    ..The discovery of abnormal iron tests in a C282Y heterozygote should lead to workup for other causes of iron overload...
  38. ncbi Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases
    Ludivine Falize
    Service des Maladies du Foie, CHU Pontchaillou, Rennes, France
    Hepatology 44:472-7. 2006
    ..If confirmed on larger series, this could modify the ultrasound screening policy of hepatocellular carcinoma in genetic hemochromatosis...
  39. ncbi [Non-HFE related hereditary iron overload]
    Pierre Brissot
    Service des Maladies du Foie, CHU Pontchaillou, Rennes
    Gastroenterol Clin Biol 29:565-8. 2005
  40. ncbi Iron overload disorders
    Bruno Turlin
    Department of Pathology and INSERM U 522, Pontchaillou University Hospital, 35033 Rennes, France
    Clin Liver Dis 6:481-96, viii. 2002
    ..A systematic reasoning based on a strict semiological approach allows for guiding the clinician. Iron overload syndromes do not amount to genetic hemochromatosis only...
  41. ncbi [Disulone and hepatosiderosis]
    L Darrieux
    Service de Dermatologie, CHU Pontchaillou, Cedex, France
    Ann Dermatol Venereol 133:683-5. 2006
    ..Moreover in France, dapsone is marketed in combination with iron oxalate, with the attendant risk of iron overload. These cases raise the question of the need for serum ferritin analysis during Disulone therapy...
  42. ncbi Comparison of blood tests for liver fibrosis specific or not to NAFLD
    Paul Cales
    Service d Hepato Gastroenterologie, CHU, 49933 Angers cedex 09, France
    J Hepatol 50:165-73. 2009
    ..To compare blood tests of liver fibrosis specific for NAFLD: the FibroMeter NAFLD and the NAFLD fibrosis score (NFSA) with a non-specific test, APRI...
  43. ncbi Clinical aspects of hemochromatosis
    P Brissot
    Clinique des Maladies du Foie and Liver Research Unit INSERM U 522, University Hospital Pontchaillou, rue H Le Guilloux, 35033 Rennes, France
    Transfus Sci 23:193-200. 2000
    ..The discovery of the HFE gene has also paved the road for the individualization of other types of iron overload syndromes which are not HFE-related...
  44. ncbi Liver transplantation for hepatocellular carcinoma without preoperative tumor biopsy
    Philippe Compagnon
    Service de Chirurgie Hépato biliaire et Digestive, Hopital Pontchaillou, INSERM U522, Universite Rennes 1, Rennes, France
    Transplantation 86:1068-76. 2008
    ..Progress in liver imaging has made pretransplantation tumor biopsy no longer systematic in patients with hepatocellular carcinoma (HCC)...
  45. ncbi Plasma palmitoleic acid, a product of stearoyl-coA desaturase activity, is an independent marker of triglyceridemia and abdominal adiposity
    François Paillard
    Cardiovascular Prevention Center, Departement de Cardiologie, CHU Pontchaillou, 2 rue Henri Le Guilloux, 35033 Rennes, France
    Nutr Metab Cardiovasc Dis 18:436-40. 2008
    ..The aim was to assess the relationship of plasma palmitoleic acid content, a product of SCD activity, with triglyceridemia and abdominal adiposity in humans...
  46. ncbi Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing
    Bartholomeus Johannes Veldt
    Service des Maladies du Foie and INSERM U522, Centre Hospitalier Universitaire, , 35033 Rennes, France
    J Hepatol 36:93-8. 2002
    ..OLT should be considered when improvement in liver function is lacking after 3 months of abstinence...
  47. ncbi High rate of long-term virological response after a 1-year course of interferon +/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial
    Eveline J Boucher
    Service des Maladies du Foie and INSERM U 522, Hopital Pontchaillou, 35033 Rennes, France
    Liver Int 23:255-61. 2003
    ..Therefore, the therapeutic schedule presented here can be considered of particular interest for the retreatment of relapsers...
  48. ncbi Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance
    Jacqueline Milet
    INSERM U535, Villejuif, France
    Am J Hum Genet 81:799-807. 2007
    ..Our results also highlight the BMP regulation pathway as a good candidate for identification of new modifier genes...
  49. ncbi A nomogram to predict C282Y hemochromatosis
    Jerry S McGrath
    Department of Medicine, London Health Sciences Centre, Ontario, Canada
    J Lab Clin Med 140:6-8. 2002
    ..9-8.1). This approach allows the clinician to predict the probability of a patient's being a C282Y homozygote over a wide range of ferritin and transferrin saturation values instead of above a particular threshold...
  50. ncbi [Non alcoholic steatohepatitis: a multifactorial, frequent, paucysymptomatic liver disease with a fibrotic outcome]
    Nadia Laroussi
    , , Saint-Etienne, France
    Gastroenterol Clin Biol 26:475-9. 2002
    ..A high prevalence of autoantibodies, iron overload and mutation of the HFE gene were detected. Non alcoholic steatohepatitis should be diagnosed because it can be associated with cirrhosis...
  51. ncbi Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis
    Melanie Beaton
    London Health Sciences Centre, London, Ontario, Canada
    Hepatology 36:673-8. 2002
    ....
  52. ncbi [Pathophysiology and genetics of classic HFE (type 1) hemochromatosis]
    Olivier Loreal
    INSERM U 522, IFR140, Universite de Rennes 1
    Presse Med 36:1271-7. 2007
    ..Cys282Tyr mutation of the HFE gene; these new genes include those of hemojuvelin (HJV), transferrin receptor 2 (TfR2), and hepcidin (HAMP)...
  53. ncbi [Interview: questions to professor Yves Deugnier]
    Yves Deugnier
    Gastroenterol Clin Biol 27:814-6. 2003
  54. ncbi High vascular endothelial growth factor (VEGF) expression in chemically-induced hepatic microcancers in mice
    Bruno Turlin
    Laboratory of Pathology, University Hospital Pontchaillou, 2 rue Henri Le Guilloux, 35033 Rennes Cedex, France
    J Hepatol 37:620-4. 2002
    ..Vascular endothelial growth factor (VEGF) could be involved in such vascular extension. The aim of our study was to evaluate the in situ VEGF expression in chemically-induced microcancers...
  55. ncbi Importance of the functional sensitivity determination of a serum hyaluronic acid assay for the prediction of liver fibrosis in patients with features of the metabolic syndrome
    Catherine Massart
    Clin Chem Lab Med 44:505-7. 2006